Assaying and Classifying T Cell Function by Cell Morphology by Xin Wang, Stacey M. Fernandes, Jennifer R. Brown, Lance C. Kam

Get full text

4321 Personalization of T cell production for cellular immunotherapy by Dennis Jinglun Yuan, Shuai Shao, Joanne H Lee, Stacey M Fernandes, Jennifer R Brown, Lance C Kam

Get full text

IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib by Veronika Sandova, Gabriela Mladonicka Pavlasova, Vaclav Seda, Katerina Amruz Cerna, Sonali Sharma, Veronika Palusova, Yvona Brychtova, Sarka Pospisilova, Stacey M. Fernandes, Anna Panovska, Michael Doubek, Matthew S. Davids, Jennifer R. Brown, Jiri Mayer, Marek Mraz

Get full text

Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors by Deepti Gadi, Stephen P. Martindale, Pui Yan Chiu, Jasneet Khalsa, Pei-Hsuan Chen, Stacey M. Fernandes, Zixu Wang, Svitlana Tyekucheva, John-Hanson Machado, David C. Fisher, Philippe Armand, Matthew S. Davids, Scott Rodig, Barbara Sherry, Jennifer R. Brown

Get full text

BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia by Stephen Jun Fei Chong, Junyan Lu, Rebecca Valentin, Timothy Z. Lehmberg, Jie Qing Eu, Jing Wang, Fen Zhu, Li Ren Kong, Stacey M. Fernandes, Jeremy Zhang, Charles Herbaux, Boon Cher Goh, Jennifer R. Brown, Carsten U. Niemann, Wolfgang Huber, Thorsten Zenz, Matthew S. Davids

Get full text

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma by Jennifer R. Brown, Bradley Messmer, Lillian Werner, Matthew S. Davids, Evgeny Mikler, Jeffrey G. Supko, David C. Fisher, Ann S. LaCasce, Philippe Armand, Eric Jacobsen, Virginia Dalton, Bethany Tesar, Stacey M. Fernandes, Sean McDonough, Jerome Ritz, Laura Rassenti, Thomas J. Kipps, Donna Neuberg, Arnold S. Freedman

Get full text

S142: FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY by Laura Ondrisova, Vaclav Seda, Eva Hoferkova, Giorgia Chiodin, Krystof Hlavac, Lenka Kostalova, Daniel Filip, Pedro Faria Zeni, Anna Panovska, Karla Plevova, Sarka Pospisilova, Martin Simkovic, Filip Vrbacky, Daniel Lysak, Stacey M. Fernandes, Matthew S. Davids, Alba Maiques-Diaz, Stella Charalampopoulou, Jose I Martin-Subero, Jennifer R Brown, Michael Doubek, Francesco Forconi, Jiri Mayer, Marek Mraz

Get full text